Haoxi Health Technology Limited (Class A) (HAO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.92 -5.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.90

Haoxi Health Technology Limited (Class A) (HAO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HAO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HAO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Haoxi Health Technology Limited (Class A) (NASDAQ: HAO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.92 (-5.88% 1D, market cap $1.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 132 tracked Communication Services issuers, HAO ranks #102 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HAO compare to TNMG and FCDH in the Communication Services sector?
▼

Within the Communication Services sector (Advertising), HAO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of —. By comparison, TNMG (TNL Mediagene) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $2.3M) and FCDH (Forcendra Holding Limited (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.1M). Among the 5-stock peer group, HAO leads on earnings multiple (N/A) while YDKG leads on capital efficiency (-11.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HAO?
▼

Per HAO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001954594), Haoxi Health Technology Limited (Class A) generated $537.6K in revenue (-54.6% YoY), $3.9M in net income, and -$3.4M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Communication Services with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.90 (-1.25%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$4570 Bull$2 Base$1 Bear
📬 FREE HAO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HAO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY HAO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 92.8% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$2.44-15.6% Next Q
Q2 (-2Q)
41
Grade D$2.06-4.9% Next Q
Q3 (-1Q)
39
Grade E$1.96-2% Next Q
Current
36
Grade D-$1.92-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HAO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HAO currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Communication Services with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.65) and Max Pain ($2.02) forces dealer call-delta covering toward $4,569.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HAO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HAO Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How HAO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.0MGross Profit $927.8K (92.8%)Cost of Sales $72.3KOp Profit $0 (0%)OpEx (R&D/SG&A) $927.8KNet Profit$3.9M (387.7%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $28.2M
FY24
Rev $1.2M
FY25
Rev $537.6K
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$537.6K98%-80%$3.9M-$3.4M15%
FY 2024$1.2M98%85%$1.3M-$802.9K7.2%
FY 2023$28.2M92%4.2%$969.8K-$872.1K15%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HAO)

  • ✓Walkthrough of HAO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HAO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.89%▲ RESISTANCE BREAKOUT
2026-11-02O $2.02H $2.04L $1.92C $1.92VOL 26.1K
RES: $1.07SUP: $0.76SMA50: $2.65SMA200: $1,164.8
$3,196.9$2,330.9$1,464.9$598.8$-267.16RES $1.07SUP $0.76$1.922026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HAO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -54.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HAO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HAO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HAO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HAO)

Communication Services Rank #102 of 132 ⚔️ TNMG vs HAO Full Matrix →

1. Head-to-Head Communication Services Peer Comparison (HAO vs. TNMG, FCDH, YDKG, INUV)

Industry: Advertising (23 Tracked Issuers)

Across 132 tracked Communication Services securities in the Roarable RQD universe, Haoxi Health Technology Limited (Class A) (HAO) ranks #102 by composite RQD confidence (36/100, grade D-) and #131 by equity capitalization ($1.3M). Within this direct 5-issuer industry benchmark cohort, HAO leads on earnings valuation at N/A trailing P/E, while YDKG leads on capital efficiency and profitability with -11.5% ROIC and -2.5% gross margin. YDKG currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with HAO at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HAO ACTIVE
Haoxi Health Technology Limited (Class A)
D- 36/100 — 96.0% — -5.88% $1.3M Benchmark Subject
TNMG
TNL Mediagene
D 46/100 — — — +27.54% $2.3M /tnmg-vs-hao →
FCDH
Forcendra Holding Limited (Class A)
E 26/100 — 23.7% -35.0% -2.72% $3.1M /fcdh-vs-hao →
YDKG
Yueda Digital Holding Class A Ordinary Share
D 50/100 — -2.5% -11.5% -2.17% $5.1M /ydkg-vs-hao →
INUV
Inuvo Inc.
E 26/100 — 74.5% -35.0% -4.36% $7.2M /inuv-vs-hao →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001954594

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Haoxi Health Technology Limited (Class A) (HAO) reported GAAP revenue of $537.6K (-54.6% vs. FY2024 revenue of $1.2M , and -98.1% cumulative change since FY2023) , GAAP net income of $3.9M, operating cash flow of -$3.4M, and free cash flow of -$3.4M (-318.2% YoY). On the balance sheet, HAO closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $537.6K $3.9M -$3.4M -$3.4M — —
FY2024 (FY) 2024-06-30 $1.2M $1.3M -$747.6K -$802.9K $22.1M —
FY2023 (FY) 2023-06-30 $28.2M $969.8K -$872.1K -$872.1K — —

3. HAO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HAO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Haoxi Health Technology Limited (Class A) (NASDAQ: HAO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.92 (-5.88% 1D, market cap $1.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 132 tracked Communication Services issuers, HAO ranks #102 in composite RQD confidence.

How does HAO compare to TNMG and FCDH in the Communication Services sector?

Within the Communication Services sector (Advertising), HAO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of —. By comparison, TNMG (TNL Mediagene) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $2.3M) and FCDH (Forcendra Holding Limited (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.1M). Among the 5-stock peer group, HAO leads on earnings multiple (N/A) while YDKG leads on capital efficiency (-11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HAO?

Per HAO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001954594), Haoxi Health Technology Limited (Class A) generated $537.6K in revenue (-54.6% YoY), $3.9M in net income, and -$3.4M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Communication Services with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HAO trading relative to its 50-day, 200-day, and 52-week technical levels?

HAO last traded at $1.92 (-5.88% on volume of 37,902 shares), positioning the stock -27.55% below its 50-day simple moving average ($2.65) and -99.84% below its 200-day simple moving average ($1,164.79). Across its 52-week range of $1.60 to $4,352.00, HAO sits at the 0.0% percentile with a 14-day RSI of 37.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.68 to $2.16).

HAO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Haoxi Health Technology Limited (Class A) (HAO)?

In FY 2025 (10-K), HAO converted $1.0M of revenue into a 92.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

HAO — Haoxi Health Technology Limited (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:55:03Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HAO scores 36 out of 100 and receives a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

  • Fundamental Cash Engine: 8 / 20. The rating reports ROIC at 0% and FCF yield at 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash relative to its valuation, so there is little cash-based support for the share price.
  • Whale 13F Flow: 3 / 20. This pillar reflects institutional accumulation and options positioning, and it is the lowest-scoring pillar. Weak institutional support means fewer large holders are signaling conviction, which can increase the price impact of any selling.
  • Insider Conviction: 7 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider or congressional buying conviction.
  • Macro Regime Fit: 8 / 20. The rating reports Beta of 1.0 and a sector sensitivity assessment. A beta of 1.0 means the stock moves in line with the broader market, so it offers no defensive cushion and no special leverage to a market move in either direction.
  • Forensic Balance Sheet: 10 / 20. The rating cites Altman Z of 2.5, Piotroski F of 3/9, and Debt/Equity of 0.5. These figures sit in a middle-to-weak zone, which signals balance-sheet fragility rather than robust financial health.

Investor implications: The upside case depends on a turnaround in operating economics, since current cash-based metrics are at zero. Valuation is difficult to anchor because P/E and EPS are not available in source data. The strongest near-term drivers of volatility are the pillars with the lowest scores (institutional flow and insider conviction), which suggest limited support during drawdowns. This is an educational reading of the rating, not personalized financial advice.

Business

Haoxi Health Technology Limited (Class A) is a NASDAQ-listed issuer classified under the Communication Services sector and the Advertising industry, per the profile. The source data does not describe its products, customers, or revenue model beyond the sector and industry classification. Operating margin is reported at -60% and gross margin at 96% per the market data section.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.5M$-2.0M$3.9MN/A$-3.4MN/AN/A
FY 2024$1.2M$1.7M$1.3MN/A$-0.8MN/AN/A
FY 2023$28.2M$1.2M$1.0MN/A$-0.9MN/AN/A

Per the SEC financials, revenue declined from $28.2M (FY 2023) to $1.2M (FY 2024) to $0.5M (FY 2025), while free cash flow was negative in each reported year. Net income for FY 2025 ($3.9M) is well above operating income ($-2.0M), a divergence the source data does not explain. Per the market data, ROIC is 0%, FCF yield is 0%, and net margin is 68%. The Altman Z-Score (2.5) and Piotroski F-Score (3/9) are cited in the Roarable RQD rating; the source data does not provide a separate cash or debt balance for the balance sheet.

Recent Catalysts & News Wire Analysis

Per the news feed, all six items are tagged to HAO with a YELLOW light and MARKET WIRE impact label:

  • A TradingView item on price-to-book forward and a TradingView item on estimates, neither with content beyond a generic description.
  • Yahoo Finance reports on a reverse share split for Zhibao Technology Inc. and on a 1-for-20 reverse stock split for Huachen AI Parking Management Technology Holding Co., Ltd. effective October 23, 2026. The source data does not state whether either item applies to HAO's own share structure.
  • A Benzinga premarket movers piece and an RTTNews morning movers piece, both referencing other tickers.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Catalyst risk items for a prospective investor are the reverse-split references, which may signal share-count changes, and the absence of substantive company-specific news in the feed.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream links are recorded, and no proprietary signals are provided. The graph classifies the sector as Communication Services and the industry as Advertising, but records no dependency relationships. A prospective investor should therefore treat second-order ripple effects as unmapped in the source data. Any sector-level sensitivity would have to be inferred from the RQD macro regime pillar (Beta of 1.0), which does not identify specific supplier or customer exposures.

Open Questions

  • What is the company's actual business model and primary revenue source, given that the source data reports revenue falling from $28.2M to $0.5M over three fiscal years?
  • Why is FY 2025 net income ($3.9M) positive while operating income ($-2.0M) and free cash flow ($-3.4M) are negative, and what drives the gap?
  • Do the reverse stock split references in the news feed apply to HAO's share structure, and if so, what is the effective ratio and date?
  • What are the company's cash and total debt balances, since the financials report both as N/A?
  • What explains the extreme 52-week range of $1.6 to $4352 in the market data, and whether it reflects a corporate action or data anomaly?

HAO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Haoxi Health Technology Limited (Class A) (HAO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HAO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HAO Bull vs. Bear Conversation Board — What's Your Call at $1.92?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HAO 🐻 67% BEARISH CONVICTION
1. Pick Your Side on HAO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.80 (-11.8%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is HAO (D- • RQD 36/100) a Buy at $2.04?

Welcome to the HAO (Haoxi Health Technology Limited (Class A)) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Advertising. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.65 (-19.1%)
Spot @ $2.04

Pump the brakes on HAO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HAO, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Haoxi Health Technology Limited (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.39 (+17.2%)
Spot @ $2.04

HAO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HAO, the market is fixating on short-term headline noise in Advertising and ignoring the balance sheet and cash flow trajectory. At $2.04 (52-wk range $1.60 - $4352.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%